Skip to main content

Year: 2025

Twin Peaks Opens New Lodge in Algonquin, Illinois, on March 17

Twin Hospitality Group Inc.Twin Peaks Opens New Lodge in Algonquin, Illinois, on March 17Ultimate sports lodge brings scratch-made food, 29-degree draft beer, and premium sports watching atmosphere to the Chicago area — just in time for St. Patrick’s Day Chicago, Ill., March 17, 2025 (GLOBE NEWSWIRE) — Twin Hospitality Group Inc. (Nasdaq: TWNP), the parent company of Twin Peaks Restaurant, is bringing the luck of the lodge to the Chicago area with its newest location in Algonquin, opening Monday, March 17, creating the perfect spot for St. Patrick’s Day celebrations. Known for its 29-degree draft beer, made-from-scratch kitchen and unbeatable game-day environment, this marks Twin Peaks’ fourth location in Illinois and the 116th lodge across the U.S. and Mexico. Located at 1520 South Randall Road in the Algonquin Commons,...

Continue reading

WillScot Announces Modifications to Consent Solicitations to Amend its Senior Secured Notes Due 2029 and Senior Secured Notes due 2031

PHOENIX, March 17, 2025 (GLOBE NEWSWIRE) — WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced it is amending the Consent Solicitations of its indirect subsidiary, Williams Scotsman, Inc. (“WSI”), soliciting consents (“Consents”) from holders of its existing 6.625% Senior Secured Notes due 2029 (the “2029 Notes”) and the holders of its 7.375% Senior Secured Notes due 2031 (the “2031 Notes” and, together with the 2029 Notes, the “Existing Notes”) as of the record date of March 11, 2025 (the “Record Date”) for the adoption of certain amendments (the “Proposed Amendments”) to the indentures governing the Existing Notes. The Consent Solicitations for each series of Existing Notes (collectively, the “Consent Solicitations” and, with respect to each...

Continue reading

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome measure- -Plan to initiate Phase 3 trial in mid-2026 following meeting with regulatory authorities- -Awarded 2024 Prix Galien USA Award as “Best Startup” by the Galien Foundation- BOSTON, March 17, 2025 (GLOBE NEWSWIRE) —  CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported its financial results for the fourth quarter and full year ended December 31, 2024. “Following the highly encouraging 16-week extension results from our Phase 2b RewinD-LB trial, we believe we have established proof-of-concept for neflamapimod as a potential...

Continue reading

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI) -refractory advanced or metastatic solid tumors. Interim results demonstrated PLN-101095 anti-tumor activity in combination with pembrolizumab, with three partial responses observed in cohort three at the 1000 mg administered orally twice daily (BID) dose, representing a...

Continue reading

Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects

The US Government Granted Athena GTX a $2,866,000 Final Development Contract Award! JACKSON CENTER, Pa., March 17, 2025 (GLOBE NEWSWIRE) — Halberd Corporation (OTC: HALB) partnered with Athena GTX on a profit-sharing agreement over a year ago. This enabled Halberd to utilize Athena’s expertise and experience in dealing with the federal government. Of the two technologies associated with Traumatic Brain Injuries (TBI)/Suicide Ideation for which we chose to pursue government funding, Athena’s success via the WatchDawg® Pilot Study was chosen to lead the Suicide Ideation treatment project, while Halberd, via the successful Mississippi State University initial animal tests, leads the TBI mitigation nasal spray development program. The website we established to do the hard work on market development and FDA clearance for our LDX adjunct...

Continue reading

Sintx Technologies Announces Board Chairman Transition

SALT LAKE CITY, Utah, March 17, 2025 (GLOBE NEWSWIRE) — Sintx Technologies, Inc. (NASDAQ: SINT) (“Sintx” or the “Company”), a leader in advanced ceramics for medical device and technical applications, today announced that Dr. Sonny Bal has retired as Chairman of the Board, and the Board of Directors has unanimously appointed Eric Olson, the Company’s Chief Executive Officer, as its new Chairman, effective immediately. Dr. Bal, who has served as Chairman since 2015, has played a crucial role in driving Sintx’s transformation, strengthening its core business, and positioning the Company for growth in the advanced materials sectors. He will continue to support the Company as a member of the Board of Directors, ensuring continuity as Sintx executes on its strategic objectives. “On behalf of the Board and the entire Sintx team, I want...

Continue reading

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

 New Analyses Related to Aficamten Expand on its Metabolism Pathways,Treatment Effect Associated with Combination Therapy with Disopyramideand Longer-Term Effect on Cardiac Structure and Function SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic cardiomyopathy (HCM), at the American College of Cardiology (ACC) Annual Scientific Session & Expo taking place from March 29, 2025–March 31, 2025 in Chicago, IL. “We are pleased to be sharing several new analyses relating to aficamten at the upcoming ACC Scientific Session & Expo,” said Stephen Heitner, M.D., Vice President, Head of Clinical Research. “The presentations describe the drug metabolism of aficamten,...

Continue reading

Signify share repurchase period update

Press Release March 17, 2025 Signify share repurchase period update Eindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced that it has repurchased 145,733 shares in the period March 10 to March 14, 2025. The shares were repurchased at an average price of EUR 20.51 per share and an aggregate amount of EUR 3.0 million. Signify will use these repurchased shares to cover obligations arising from Signify’s long-term incentive performance share plan and other employee share plans. The repurchases were made as part of the company’s share repurchase program, which was announced on February 4, 2025. The total number of shares repurchased under this program to date is 830,209 shares for a total consideration of EUR 17.2 million. Details on the share buyback transactions can be found here.   —...

Continue reading

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology

    The Annual Meeting is the foremost educational and scientific event for gynecologic oncologistsStenoparib has shown clinical benefit in heavily pre-treated patients, including those with platinum-resistant and refractory ovarian cancerFindings may reflect stenoparib’s dual PARP/Wnt pathway inhibitionBoston (March 17, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor— announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in advanced Ovarian Cancer at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer, held March 14-17 in Seattle, Washington. SGO is the world’s premier organization for...

Continue reading

Volaris Automotive Acquires Britehouse Automotive, Expanding Its Footprint in the Automotive Software Solutions Market

Strategic Acquisition Strengthens Volaris Automotive’s Offerings and Market Reach TORONTO, March 17, 2025 (GLOBE NEWSWIRE) — Volaris Automotive, an acquirer of specialized software companies serving the automotive industry, today announced the acquisition of Britehouse Automotive, a prominent developer of innovative automotive software platforms. This continues Volaris Automotive’s initiative to further expand its reach in the auto sector. Founded in 1983 in South Africa, Britehouse Automotive delivers a comprehensive dealer management software (DMS) along with custom digital solutions. With over 40 years of experience, the company has expanded its reach to become the premiere choice for auto companies across South Africa, Eswatini, Botswana, Lesotho and Namibia. In 2010, Japan-based Nippon Telegraph & Telephone Corporation...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.